Bergmann J. Anthony's most recent trade in Capricor Therapeutics Inc was a trade of 24,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 25, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 24,100 | 91,980 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.18 per share. | 25 Jun 2026 | 24,100 | 35,323 (0%) | 0% | 3.2 | 76,638 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.38 per share. | 25 Jun 2026 | 24,100 | 11,223 (0%) | 0% | 30.4 | 732,158 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 22 Jun 2026 | 500 | 11,223 (0%) | 0% | 30 | 15,000 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 500 | 116,480 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.18 per share. | 22 Jun 2026 | 500 | 11,723 (0%) | 0% | 3.2 | 1,590 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 400 | 116,080 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 22 Jun 2026 | 400 | 11,223 (0%) | 0% | 30 | 12,000 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.18 per share. | 22 Jun 2026 | 400 | 11,623 (0%) | 0% | 3.2 | 1,272 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 3,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 18 May 2026 | 3,000 | 11,223 (0%) | 0% | 1.4 | 4,170 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 25,000 | 116,980 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 31.70 per share. | 01 May 2026 | 25,000 | 8,223 (0%) | 0% | 31.7 | 792,540 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.18 per share. | 01 May 2026 | 25,000 | 33,223 (0%) | 0% | 3.2 | 79,500 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.18 per share. | 31 Mar 2026 | 25,000 | 33,223 (0%) | 0% | 3.2 | 79,500 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.13 per share. | 31 Mar 2026 | 25,000 | 8,223 (0%) | 0% | 30.1 | 753,153 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 25,000 | 141,980 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 2,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 03 Mar 2025 | 2,500 | 8,223 (0%) | 0% | 1.4 | 3,475 | Common Stock |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,170 | 6,170 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 3,342 | 5,723 (0%) | 0% | 0 | Common Stock | |
| Capricor Therapeutics Inc | Bergmann J. Anthony | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | J. Anthony Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 9,692 | 9,692 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 166,980 | 166,980 | - | - | Stock Option (Right to Buy) |